Dr. Srinivasan Ramanuja, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
1421 Premier Dr, Mankato Clinic Wickersham
Mankato, MN 56001
Who else practices at this address →
Blue Earth County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 92
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
MN license 49842 · CA license A88016 (first issued 2004; delinquent)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Mankato Clinic LTD (242 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 92
- Services billed
- 7,158
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 722 | 14 |
| Injection of drug or substance under skin or into muscle | 145 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 102 | 68 |
| Administration and interpretation of patient-focused health risk assessment | 47 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Mankato, MN | 175 |
| Fluticasone Propionate Other prescribers in Mankato, MN | 169 |
| Azelastine Hcl Other prescribers in Mankato, MN | 81 |
| Levocetirizine Dihydrochloride Other prescribers in Mankato, MN | 80 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Mankato, MN | 58 |
| Dulera (mometasone/formoterol) Other prescribers in Mankato, MN | 52 |
| Epinephrine Other prescribers in Mankato, MN | 41 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Mankato, MN | 40 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Mankato, MN | 37 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Mankato, MN | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 33 payments worth $15,352 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $15,097 |
|---|---|
| Ars Pharmaceuticals Operations, Inc. | $49.36 |
| Ionis Pharmaceuticals, Inc. | $40.15 |
| Cycle Pharmaceuticals Inc | $24.10 |
| Optinose US, Inc. | $23.52 |
| Pharming Healthcare, Inc. | $20.00 |
| Insmed, Inc. | $17.68 |
| Novartis Pharmaceuticals Corporation | $17.51 |
| Compensation for services other than consulting (speaking, faculty) | $13,650 |
|---|---|
| Travel and Lodging | $1,075 |
| Food and Beverage | $601 |
| Education | $25.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,400 |
| AstraZeneca Pharmaceuticals LP Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,400 |
| AstraZeneca Pharmaceuticals LP Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,400 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $2,950 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Bismarck, ND · in-kind Company’s descriptionSpeaker Expenses | $537 |
| AstraZeneca Pharmaceuticals LP Nov 9, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Bismarck, ND · in-kind Company’s descriptionSpeaker Expenses | $144 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Bismarck, ND · in-kind Company’s descriptionSpeaker Expenses | $141 |
| AstraZeneca Pharmaceuticals LP Jul 8, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Minneapolis, MN · in-kind Company’s descriptionSpeaker Expenses | $137 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 9, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Ionis Pharmaceuticals, Inc. Oct 2, 2025 | Education in-kind | $25.00 |
| AstraZeneca Pharmaceuticals LP Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,400 |
| AstraZeneca Pharmaceuticals LP Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,400 |
| AstraZeneca Pharmaceuticals LP Jul 21, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Rochester, MN · in-kind Company’s descriptionSpeaker Expenses | $116 |
| AstraZeneca Pharmaceuticals LP Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Jul 8, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Minneapolis, MN · in-kind Company’s descriptionSpeaker Expenses | $137 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $2,950 |
| AstraZeneca Pharmaceuticals LP Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,400 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Bismarck, ND · in-kind Company’s descriptionSpeaker Expenses | $537 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Bismarck, ND · in-kind Company’s descriptionSpeaker Expenses | $144 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Bismarck, ND · in-kind Company’s descriptionSpeaker Expenses | $141 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $168,568 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, parallel group, multi-center study to eval
GlaxoSmithKline, LLC. - Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT06102005 - Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Sanofi US Services Inc. · Active, not recruiting · NCT06676319 - A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.